2025 Q3 -tulosraportti
38 päivää sitten32 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
2 721
Myynti
Määrä
2 381
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 193 | - | - | ||
| 150 | - | - | ||
| 39 | - | - | ||
| 48 | - | - | ||
| 120 | - | - |
Ylin
9,43VWAP
Alin
8,71VaihtoMäärä
0,7 83 310
VWAP
Ylin
9,43Alin
8,71VaihtoMäärä
0,7 83 310
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 83 310 | 83 310 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 83 310 | 83 310 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 20.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 24.10. | |
| 2025 Q2 -tulosraportti | 26.8. | |
| 2025 Q1 -tulosraportti | 8.5. | |
| 2024 Q4 -tulosraportti | 20.2. | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 päivää sitten · MuokattuFor those wondering why it takes 6 months to resubmit: this is not a terribly uncommon timeframe within pharma. Firstly, it appears from what Xbrane has announced about their CMO that the relevant observations must be rectified during a planned shutdown. It is generally the case in the pharmaceutical industry that production is declassified twice annually (it is a regulatory requirement to reclassify regularly), and in connection with this, reconstruction and maintenance are carried out that cannot be performed under classified conditions. These are usually planned long in advance and typically take place in July and December (in some parts of the world they may be placed differently - they are often done in connection with major holidays, as there is less need for personnel during a shutdown). So, it is quite natural that OneSource chooses to carry out reconstruction and requalification in connection with the shutdown in December. When that is finished in early-mid January, validation activities usually need to be reported – that also typically takes 1-2 months – and then we are at March 2026. So, even if it might seem incredibly slow, it actually makes sense if you know a bit about how things are done in aseptic production. (In fact, I wouldn't be surprised if the resubmission is delayed by a couple of months – it's not uncommon for reporting of major changes to be prolonged – but let's cross that bridge when we come to it.)
·19.11. · MuokattuI don't know this market, nor the FDA approval procedure, but..... How can it take so long to answer the questions from the FDA, and even more, why haven't they addressed what was previously requested by the FDA!? Perhaps they should release more detailed information about what the FDA is not satisfied with and also why it takes over 6 months to even answer these questions and fix the problems. Everything has supposedly been ready to launch on the market for a long time, and the contamination problem has been resolved, it was announced earlier. It has long felt like they don't really know what they're doing and have also gotten partners who don't really know what they're doing either. Or is it that they are bickering with the FDA, who wants to teach them a lesson.....!? I wonder what Six Rays thinks about this after their latest purchase...... https://www.nordnet.se/marknaden/nyheter/4fbc02ce-ac6d-43ee-a592-503dd93957f5·20.11.After reading the latest Q&A, my clear impression is that the friction is between the FDA and the CMO, not directly Xbrane. To what extent it is politically motivated is hard to say. It sounds like there haven't been repeat observations but there have been other, new, unspecified challenges at the site. To be completely honest, I also don't fully understand the choice of an Indian CMO. Indian F&F sites have a rather tarnished reputation in the industry, and shipping-wise, it's far from the markets they are trying to reach right now. It seems like a corner has been cut that shouldn't have been cut.
·14.11.Has there been any new information about CLRn? Xbrane said on October 20 that they expected updates by the end of the week (October 24). Now three weeks have passed without me seeing anything. Has anyone else picked up on something I missed?
·6.11.Haven't kept track of the shareholder list, when did Sixrays become a major shareholder? Were they part of any previous share issue?
·6.11.No, don't know that much. Maybe just an investment. They went over 5% on July 11. So they are not new. https://mfn.se/cis/a/fi-se/finansinspektionen-flaggningsmeddelande-i-xbrane-biopharma-ab-c0ad915e
·5.11.Damn, what a shitty management that burns money like no other, they get far too high salaries -they can't handle sales- they can't enter into partnership agreements that are favorable for the shareholders - they can't control costs. = incompetent management, incredible that this can happen·6.11. · MuokattuAs I read it, the board and management (14 people) received a total of 13,2 mio. SEK in salary in 2024. Including pension, it was 15,9 mio. SEK. Now that they have not delivered on either FDA or sales in Europe and the rest of the world, they should take a pay cut or be replaced. With a salary of 2,665 mio. SEK excl. pension (3,366 mio. SEK incl. pension), I believe that it is CEO Martin Åmark who should be replaced. He is responsible. He has probably tried. But now one must try something new.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
38 päivää sitten32 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sitten · MuokattuFor those wondering why it takes 6 months to resubmit: this is not a terribly uncommon timeframe within pharma. Firstly, it appears from what Xbrane has announced about their CMO that the relevant observations must be rectified during a planned shutdown. It is generally the case in the pharmaceutical industry that production is declassified twice annually (it is a regulatory requirement to reclassify regularly), and in connection with this, reconstruction and maintenance are carried out that cannot be performed under classified conditions. These are usually planned long in advance and typically take place in July and December (in some parts of the world they may be placed differently - they are often done in connection with major holidays, as there is less need for personnel during a shutdown). So, it is quite natural that OneSource chooses to carry out reconstruction and requalification in connection with the shutdown in December. When that is finished in early-mid January, validation activities usually need to be reported – that also typically takes 1-2 months – and then we are at March 2026. So, even if it might seem incredibly slow, it actually makes sense if you know a bit about how things are done in aseptic production. (In fact, I wouldn't be surprised if the resubmission is delayed by a couple of months – it's not uncommon for reporting of major changes to be prolonged – but let's cross that bridge when we come to it.)
- ·19.11. · MuokattuI don't know this market, nor the FDA approval procedure, but..... How can it take so long to answer the questions from the FDA, and even more, why haven't they addressed what was previously requested by the FDA!? Perhaps they should release more detailed information about what the FDA is not satisfied with and also why it takes over 6 months to even answer these questions and fix the problems. Everything has supposedly been ready to launch on the market for a long time, and the contamination problem has been resolved, it was announced earlier. It has long felt like they don't really know what they're doing and have also gotten partners who don't really know what they're doing either. Or is it that they are bickering with the FDA, who wants to teach them a lesson.....!? I wonder what Six Rays thinks about this after their latest purchase...... https://www.nordnet.se/marknaden/nyheter/4fbc02ce-ac6d-43ee-a592-503dd93957f5·20.11.After reading the latest Q&A, my clear impression is that the friction is between the FDA and the CMO, not directly Xbrane. To what extent it is politically motivated is hard to say. It sounds like there haven't been repeat observations but there have been other, new, unspecified challenges at the site. To be completely honest, I also don't fully understand the choice of an Indian CMO. Indian F&F sites have a rather tarnished reputation in the industry, and shipping-wise, it's far from the markets they are trying to reach right now. It seems like a corner has been cut that shouldn't have been cut.
- ·14.11.Has there been any new information about CLRn? Xbrane said on October 20 that they expected updates by the end of the week (October 24). Now three weeks have passed without me seeing anything. Has anyone else picked up on something I missed?
- ·6.11.Haven't kept track of the shareholder list, when did Sixrays become a major shareholder? Were they part of any previous share issue?·6.11.No, don't know that much. Maybe just an investment. They went over 5% on July 11. So they are not new. https://mfn.se/cis/a/fi-se/finansinspektionen-flaggningsmeddelande-i-xbrane-biopharma-ab-c0ad915e
- ·5.11.Damn, what a shitty management that burns money like no other, they get far too high salaries -they can't handle sales- they can't enter into partnership agreements that are favorable for the shareholders - they can't control costs. = incompetent management, incredible that this can happen·6.11. · MuokattuAs I read it, the board and management (14 people) received a total of 13,2 mio. SEK in salary in 2024. Including pension, it was 15,9 mio. SEK. Now that they have not delivered on either FDA or sales in Europe and the rest of the world, they should take a pay cut or be replaced. With a salary of 2,665 mio. SEK excl. pension (3,366 mio. SEK incl. pension), I believe that it is CEO Martin Åmark who should be replaced. He is responsible. He has probably tried. But now one must try something new.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
2 721
Myynti
Määrä
2 381
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 193 | - | - | ||
| 150 | - | - | ||
| 39 | - | - | ||
| 48 | - | - | ||
| 120 | - | - |
Ylin
9,43VWAP
Alin
8,71VaihtoMäärä
0,7 83 310
VWAP
Ylin
9,43Alin
8,71VaihtoMäärä
0,7 83 310
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 83 310 | 83 310 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 83 310 | 83 310 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 20.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 24.10. | |
| 2025 Q2 -tulosraportti | 26.8. | |
| 2025 Q1 -tulosraportti | 8.5. | |
| 2024 Q4 -tulosraportti | 20.2. | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
38 päivää sitten32 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 20.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 24.10. | |
| 2025 Q2 -tulosraportti | 26.8. | |
| 2025 Q1 -tulosraportti | 8.5. | |
| 2024 Q4 -tulosraportti | 20.2. | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sitten · MuokattuFor those wondering why it takes 6 months to resubmit: this is not a terribly uncommon timeframe within pharma. Firstly, it appears from what Xbrane has announced about their CMO that the relevant observations must be rectified during a planned shutdown. It is generally the case in the pharmaceutical industry that production is declassified twice annually (it is a regulatory requirement to reclassify regularly), and in connection with this, reconstruction and maintenance are carried out that cannot be performed under classified conditions. These are usually planned long in advance and typically take place in July and December (in some parts of the world they may be placed differently - they are often done in connection with major holidays, as there is less need for personnel during a shutdown). So, it is quite natural that OneSource chooses to carry out reconstruction and requalification in connection with the shutdown in December. When that is finished in early-mid January, validation activities usually need to be reported – that also typically takes 1-2 months – and then we are at March 2026. So, even if it might seem incredibly slow, it actually makes sense if you know a bit about how things are done in aseptic production. (In fact, I wouldn't be surprised if the resubmission is delayed by a couple of months – it's not uncommon for reporting of major changes to be prolonged – but let's cross that bridge when we come to it.)
- ·19.11. · MuokattuI don't know this market, nor the FDA approval procedure, but..... How can it take so long to answer the questions from the FDA, and even more, why haven't they addressed what was previously requested by the FDA!? Perhaps they should release more detailed information about what the FDA is not satisfied with and also why it takes over 6 months to even answer these questions and fix the problems. Everything has supposedly been ready to launch on the market for a long time, and the contamination problem has been resolved, it was announced earlier. It has long felt like they don't really know what they're doing and have also gotten partners who don't really know what they're doing either. Or is it that they are bickering with the FDA, who wants to teach them a lesson.....!? I wonder what Six Rays thinks about this after their latest purchase...... https://www.nordnet.se/marknaden/nyheter/4fbc02ce-ac6d-43ee-a592-503dd93957f5·20.11.After reading the latest Q&A, my clear impression is that the friction is between the FDA and the CMO, not directly Xbrane. To what extent it is politically motivated is hard to say. It sounds like there haven't been repeat observations but there have been other, new, unspecified challenges at the site. To be completely honest, I also don't fully understand the choice of an Indian CMO. Indian F&F sites have a rather tarnished reputation in the industry, and shipping-wise, it's far from the markets they are trying to reach right now. It seems like a corner has been cut that shouldn't have been cut.
- ·14.11.Has there been any new information about CLRn? Xbrane said on October 20 that they expected updates by the end of the week (October 24). Now three weeks have passed without me seeing anything. Has anyone else picked up on something I missed?
- ·6.11.Haven't kept track of the shareholder list, when did Sixrays become a major shareholder? Were they part of any previous share issue?·6.11.No, don't know that much. Maybe just an investment. They went over 5% on July 11. So they are not new. https://mfn.se/cis/a/fi-se/finansinspektionen-flaggningsmeddelande-i-xbrane-biopharma-ab-c0ad915e
- ·5.11.Damn, what a shitty management that burns money like no other, they get far too high salaries -they can't handle sales- they can't enter into partnership agreements that are favorable for the shareholders - they can't control costs. = incompetent management, incredible that this can happen·6.11. · MuokattuAs I read it, the board and management (14 people) received a total of 13,2 mio. SEK in salary in 2024. Including pension, it was 15,9 mio. SEK. Now that they have not delivered on either FDA or sales in Europe and the rest of the world, they should take a pay cut or be replaced. With a salary of 2,665 mio. SEK excl. pension (3,366 mio. SEK incl. pension), I believe that it is CEO Martin Åmark who should be replaced. He is responsible. He has probably tried. But now one must try something new.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
2 721
Myynti
Määrä
2 381
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 193 | - | - | ||
| 150 | - | - | ||
| 39 | - | - | ||
| 48 | - | - | ||
| 120 | - | - |
Ylin
9,43VWAP
Alin
8,71VaihtoMäärä
0,7 83 310
VWAP
Ylin
9,43Alin
8,71VaihtoMäärä
0,7 83 310
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 83 310 | 83 310 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 83 310 | 83 310 | 0 | 0 |